GAITHERSBURG, Md., Nov. 02, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its third quarter 2015 financial and operating results before the open of U.S. financial markets on Monday, November 9, 2015.
In addition, management will host a conference call to discuss the quarterly results and provide an update on corporate activities.
| Conference call details are as follows: | |||||||||
| Date: | November, 9th 2015 | ||||||||
| Time: | 8:00 am US Eastern Time (ET) | ||||||||
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287–9331 (International) | ||||||||
| Via web: | www.novavax.com, “Investors”/ “Events” | ||||||||
| Conference call replay: | |||||||||
| Dates: | Starting at 11:00 am ET, November 9, 2015 until midnight November 16, 2015 | ||||||||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | ||||||||
| Passcode: | 70778771 | ||||||||
| Via web: | www.novavax.com, “Investors”/ “Events” | ||||||||
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations ir@novavax.com 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. david.schull@russopartnersllc.com todd.davenport@russopartnersllc.com 212-845-4271
Help employers find you! Check out all the jobs and post your resume.
